BOSTON, MA—One-year outcomes from an early feasibility study (EFS) show durable improvements in symptoms and quality of life in symptomatic heart failure (HF) patients treated with a novel coronary ...
The ALT-FLOW II trial is currently enrolling up to 100 participants at sites in the United States and Oklahoma Heart Institute is one of those facilities. TULSA, Okla. - Tulsa’s Oklahoma Heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results